Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athenex - China API Business engages in Active Pharmaceutical Ingredient (API) manufacturing operations.

BUFFALO, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. All of the shares of common stock, warrants and pre-funded warrants are being offered by Athenex.

Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

American Virtual Cloud Technologies

Evofem Biosciences Inc

Here's what you need to know about buying penny stocks on August 5th? The post Penny Stocks to Buy Premarket on August 5th?

Penny Stocks to Buy Premarket on August 5th? 3 to Watch

Athenex, Inc. (NASDAQ:ATNX ) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Caileigh Dougherty - Director, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical Officer, Cell Therapy Jeff Yordon - Chief Operating Officer Joe Annoni - Chief Financial Officer Conference Call Participants Faisal Khurshid - SVB Securities Jon Miller - Evercore Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Co Operator Good day, ladies and gentlemen and welcome to the Second Quarter 2022 Athenex Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Caileigh Dougherty, Director of Investor Relations.

Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2022 Results - Earnings Call Transcript

Athenex (ATNX) delivered earnings and revenue surprises of -76.92% and 6.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q2 Loss, Lags Revenue Estimates

BUFFALO, N.Y., July 28, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the second quarter ended June 30, 2022.

Athenex Provides Second Quarter 2022 Financial Results and Business Update

BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the publication of their manuscript, “Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer”. The article, along with results, can be found on the American Society of Clinical Oncology Journal's website at this link.

Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the second quarter 2022 on Thursday, July 28, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.

Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

BUFFALO, N.Y., July 11, 2022 (GLOBE NEWSWIRE) --  Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Athenex and certain affiliates have entered into an agreement to sell all of its equity interests in its China subsidiaries, which are primarily engaged in Active Pharmaceutical Ingredient (API) manufacturing operations, to TiHe Capital (Beijing) Co., Ltd. for RMB 124.4 million, or approximately $19.0 million. Athenex will receive at least 70% of the proceeds at Closing, followed by 20% within three months after the Closing Date, and the remaining balance within six months after the Closing Date. Proceeds from the transaction will be used in part toward repaying existing debt and operating the business. The deal is subject to customary closing conditions, including obtaining certain regulatory approvals in China. Athenex and TiHe also plan to enter into a long-term supply agreement for the manufacture and supply of certain API products.

Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.

BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Daniel Lang, M.D., President, Athenex Cell Therapy, will participate in The Next Cells & Mechanisms to Watch in Oncology panel at the Truist Securities Cell Therapy Symposium on Tuesday, June 28, 2022 at 11:30 am Eastern Time in New York, NY. Company management will also participate in one-on-one investor meetings during the event.

Athenex to Participate in Truist Securities Cell Therapy Symposium

BUFFALO, N.Y., June 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the signing of a definitive agreement for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and funds managed by Oaktree Capital Management, L.P. (“Oaktree”) for $85 million. Approximately $80 million of the proceeds from the transaction will be used toward partially paying down existing debt and operating the business, with $5 million to be placed into escrow and paid to Athenex upon the satisfaction of certain conditions. The transaction is subject to customary closing conditions.

Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree

BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions. He will be replacing Kurt Gunter, MD, who has decided to pursue other opportunities outside of cell therapy.

Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy

Athenex, Inc. (NASDAQ:ATNX ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Caileigh Dougherty - Investor Relations Johnson Lau - Chief Executive Officer Daniel Lang - President, Athenex Cell Therapy Jeffrey Yordon - Chief Operating Officer Joe Annoni - Chief Financial Officer Kurt Gunter - Chief Medical Officer, Cell Therapy and Head of Regulatory Affairs Conference Call Participants Kevin DeGeeter - Oppenheimer & Co. Robyn Karnauskas - Truist Securities Jonathan Chang - SVB Leerink Yale Jen - Laidlaw & Company Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2022 Athenex Earnings Conference Call. After the presentation, there will be an opportunity to ask questions.

Athenex, Inc.'s (ATNX) CEO Johnson Lau on Q1 2022 Results - Earnings Call Transcript

Athenex (ATNX) delivered earnings and revenue surprises of -50% and 16.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

BUFFALO, N.Y., May 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the first quarter ended March 31, 2022.

Athenex Provides First Quarter 2022 Financial Results and Business Update

BUFFALO, N.Y., May 02, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will present at the upcoming ASGCT 25th Annual Meeting, taking place May 16-19, 2022, in Washington, D.C. The abstract associated with the presentation is now available on the conference website.

Athenex, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASG

BUFFALO, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the first quarter 2022 on Tuesday, May 10, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.

Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022

Athenex (ATNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Athenex (ATNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

BUFFALO, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced data from the ANCHOR Phase 1 study of KUR-502 during an oral presentation by Carlos Ramos, M.D., professor, Center for Cell and Gene Therapy, Baylor College of Medicine, at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT), and the Center for International Blood & Marrow Transplant Research (CIBMTR), taking place April 23 to 26, in Salt Lake City, UT.

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR

Athenex, Inc. (ATNX) CEO Johnson Lau on Q4 2021 Results - Earnings Call Transcript

Announces Strategic Pivot to Focus on Cell Therapy Programs

Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

BUFFALO, N.Y., March 14, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2021, on Wednesday, March 16, 2022. Athenex's management team will host a conference call and live audio webcast at 4:30 p.m. Eastern Time. Please note the call is being rescheduled from the previously announced date of March 15 at 8:00 a.m. Eastern Time.

CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022

BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately.

Athenex Announces Appointment of Chief Financial Officer

ImmunityBio

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio”), today announced the successful completion of its acquisition of the leasehold interest in an ISO Class 5 pharmaceutical manufacturing space in western New York from global pharmaceutical company Athenex, Inc. (NASDAQ: ATNX). The new state-of-the-art biotech production facility, located in Dunkirk, New York (Chautauqua County), includes clean rooms for upstream and down

ImmunityBio Completes Acquisition of Athenex's Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility

BUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the close of the sale of its leasehold interest in a manufacturing facility in Dunkirk, New York, to ImmunityBio, Inc. (NASDAQ: IBRX), for approximately $40 million.

Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility

BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, President, Athenex Cell Therapy, will present at the 11th Annual SVB Leerink Global healthcare Conference on Thursday, February 17, 2022, at 3:00 P.M. ET.

News for Athenex Stock (ATNX)